IP Library Granted Patent US 10,739,335
Granted Patent B2
US 10,739,335 · App. 15/565,753 · Granted Aug 11, 2020

Prognostic and diagnostic glycan-based biomarkers of brain damage

Inventor: Adrian Harel (Turku, FI)
Assignee: MEDICORTEX FINLAND OY
G01N33/5308G01N33/6896G01N2400/12G01N2400/38G01N2800/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,739,335
App. No.
15/565,753
Granted
Aug 11, 2020
Kind
B2
Abstract

The present disclosure relates to glycan-based biomarkers for the diagnosis or prognosis of brain damage, such as traumatic brain injury (TBI).

Claims (15)

1. A method of diagnosing a brain injury in a subject, the method comprising the steps of:

providing a sample of a bodily fluid from a subject suspected of having a brain injury, wherein said sample is a urine sample or a saliva sample;

contacting said sample with a lectin array;

determining the level of glycan in said sample bound to at least one lectin in the lectin array;

comparing the determined level of said glycan bound to at least one lectin to a level of said glycan in a sample from a healthy control;

detecting, in the sample from the subject, an elevated level of the glycan bound to at least one lectin compared to the level in the healthy control, wherein the at least one lectin is selected from the group consisting of Galanthus nivalis (GNA), Allium sativum (ASA), Narcissus pseudo narcissus (NPA), Pisum sativum (PSA), Datura stramonium (DSA), Leucoagglutinin (PHA-L), Sambucus nigra (SNA-I) and Hippeastrum hybrid (HHA);

diagnosing the presence of a brain injury in the subject from the elevated level of the glycan bound to the at least one lectin; and

performing at least one neuroimaging procedure selected from the group consisting of x-ray, computerized tomography (CT) scan, and magnetic resonance imaging (MRI) on the subject in whom the elevated level of the glycan is detected and the presence of the brain injury is diagnosed.

2. The method according to claim 1 , wherein said brain injury is selected from the group consisting of traumatic brain injury (TBI), mild TBI, severe TBI, or acquired brain injury (ABI).

3. The method according to claim 1 , wherein said determining further comprises using mass spectrometry, electrophoresis, a chromatographic method, an enzyme assay, a binding assay, or a combination thereof.

4. The method according to claim 2 , wherein said traumatic brain injury is a concussion.

5. The method according to claim 3 , wherein said determining further comprises using MALDI-TOF mass spectrometry.

6. The method according to claim 1 , wherein said determining further comprises using a reagent selected from the group consisting of a capture reagent, a detection reagent, a secondary detection reagent and a primary detection reagent.

7. The method according to claim 1 , wherein said determining is carried out by using a kit comprising at least one lectin that selectively binds to glycan in said sample, and a control for comparing to a measured value of binding.

8. The method according to claim 7 , wherein the kit further comprises a detectable label, or a colour, dye, luminescent, or fluorescent agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2017
From: HAREL, ADRIAN
To: MEDICORTEX FINLAND OY
Reel/Frame 043965/0489 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2017
From: HAREL, ADRIAN
To: MEDICORTEX FINLAND OY
Reel/Frame 043874/0615 →
Priority Claims (1)
FI 20155280 · Apr 15, 2015 · national
Continuity (1)
Related Publication 20180120305A1 · May 3, 2018
Cited By (1)
US 12,736,546